The Animal Medicines Distributors Association (AHDA) and the Animal Medicines Training Regulatory Authority (AMTRA) have both come out against the BVA's call for all anthelmintic medicines to be reclassified as POM-V, which would prevent them being prescribed by Suitably Qualified Persons (SQP).
Ian Scott, Secretary General of AHDA, said that instead of launching an attack on SQPs, the BVA should be working with them and animal owners to tackle anthelmintic resistance: "The BVA has written to the VMD to ask that all anthemintics be classified to POM-V only. This will monopolise the supply and distribution of anthelmintics for vets only. It effectively places the blame for anthelmintic resistance squarely on SQPs.
"An attempt by BVA to create a division between vets and SQPs demonstrates that the BVA is out of touch with its members.
"Both prescribing channels must work together to tackle the problem and AHDA has been working hard with vets at national and local level to ensure customers receive consistent, high quality, up-to-date and relevant advice from both channels.
"What is worrying is that the BVA attack also infers that farmer producers and equine owners are incapable of making decisions that not only affect their livelihood but cast doubt on their ability to care for their animals' welfare."
Meanwhile, Stephen Dawson, Secretary General of AMTRA said: "The large majority of SQPs deal with parasite control on a daily basis, having trained and been examined to a syllabus developed with BVA input. SQPs have to undertake compulsory continuing professional development, the majority of which includes good practice in parasite control. Therefore AMTRA has every confidence that qualified SQPs have excellent knowledge of parasitology to advise their clients on the correct choice and use of anthelmintics.
"It is important to recognise the hard work, knowledge and dedication of thousands of SQPs throughout the UK. The implication of what BVA say is that they are laying a proportion of the blame for resistance to these medicines at the door of SQPs. But the evidence isn't there: countries in Europe and elsewhere with different prescription systems, mainly though vet-only channels, still have major resistance problems. Prescription of antimicrobials by veterinary surgeons hasn't prevented concerns about prescribing practices and developing resistance. The key point is good advice from the prescriber and how they are then used in practice, rather than who prescribes them. The challenge for us all is not just to seek excellence in prescribing but also in usage on farm, something SQPs are ideally placed to do with their frequent farmer contact.
"I would urge all parties to work in partnership to ensure that best practice in prescription and use is followed by all prescribers and users. It is up to all prescribers to act responsibly, but to single out one group over another is unjustified. A pseudo-monopoly by vets on supply would do nothing to help farmers in difficult times."
Mr Dawson also expressed doubts about permanent POM-V status for new livestock anthelmintics: "While we fully support VMD's and VPC's need to be sure that the risk associated with wider availability of a new product is low, AMTRA considers that the current division in distribution classes and consequent low uptake of the newer products means that the much bigger risk is that widespread reliance on the three aging classes may be followed by reliance on just the two new classes when the older classes become unusable. Much better to have responsible prescription of all five classes now, by appropriately trained SQPs, vets and pharmacists, to ensure that there is a prospect of long term availability of effective parasite control."
The British Veterinary Association (BVA) is calling on the Veterinary Medicines Directorate to classify all anthelmintics as POM-V, so that they can only be prescribed by a veterinary surgeon, rather than by vets and Suitably Qualified Person (SQPs) as at present.
The BVA has written to the VMD to request that changes are made to the Veterinary Medicines Regulations. The BVA is also supporting the efforts of the Federation of Veterinarians of Europe in lobbying the European Commission for tighter rules to be in place across all European Member States regarding the accessibility of anthelmintics.
The BVA says that at a time when expert opinion is increasingly alarmed at the growth in resistance to anthelmintics in grazing animals, it believes that it is important that all anthelmintics be classified as POM-V so that their use is conditional on appropriate veterinary advice for all species.
Many experts in parasitology have cited the distribution of anthelmintics by SQPs in the past as one of the main reasons for the dangerous levels of resistance to anthelmintics in grazing animals in the UK at present. SQPs do not have the level of expertise that a veterinary surgeon has in veterinary parasitology.
BVA is an active member of the Responsible Use of Medicines in Agriculture (RUMA) Alliance and in 2010 BVA launched a poster and detailed guidance for vets on how to prescribe and use anthelmintics responsibly. BVA's CPD Group is also working on a programme of CPD to reinforce the responsible use of these medicines.
Peter Jones, BVA President said: "We know that resistance to anthelmintics is a major problem that must be addressed vigorously if the livestock industry is to avoid a potentially disastrous situation of being unable to tackle parasites in grazing animals.
"Anthelmintics should only be prescribed by a veterinary surgeon who has the animals under his/her care and based on a sound clinical diagnosis.
"We strongly supported the VMD's recent decision to continue to classify the new anthelmintic product containing monepantel as POM-V, but the UK stands alone in Europe in classifying other anthelmintics as POM-VPS.
"The UK must be brought in line with the rest of Europe and we need Europe-wide legislation to better control access to anthelmintics in order to safeguard the efficacy of these products in the future."
Welsh Environment Minister, John Griffiths, has announced changes to some bovine TB cattle and surveillance controls to provide a higher level of protection against the disease.
The Minister confirmed that from 1 April 2013, some existing Pre Movement Testing exemptions will be amended. The main changes concern movements from markets and common land.
New key measures are:
The Minister announced that a new dedicated TB epidemiologist was to be appointed for Wales and that he or she would work within the AHVLA and focus on specific areas or clusters of disease. The postholder will be in place by April 2013.
He also announced new advice and support to farms dealing with breakdowns: "I have also asked officials to develop a way to provide additional advice and support to farmers to clear up breakdowns more quickly and efficiently. We have started to explore how private vets could become more involved with this new initiative called the Integrated Breakdown Management Project.
"I know that bovine TB is a devastating disease that has a big impact in rural communities. Since I launched the Strategic Framework for Bovine TB Eradication last March, we have kept the programme under constant review. With the new tools I have outlined today, we are addressing TB in livestock and wildlife and maintaining an effective eradication programme for the benefit of farmers, rural communities and the economy in general."
Elanco Animal Health is reminding vets about the importance of correctly interpreting oocyst counts in the diagnosis of coccidiosis during the post lambing period.
The company says scouring lambs that are failing to thrive should immediately ring the alarm bells for coccidiosis. Typically, oocyst counts of >20,000 per gram are cited as diagnostic for coccidiosis in sheep, but counts of up to 100,000 oocysts per gram have been reported in apparently healthy lambs and disease can also occur in the presence of low or negligible counts where there is gut damage but before oocysts have been shed.1 These discrepancies can lead to misdiagnosis and as such, oocyst counts should always be interpreted with care.
Oocysts of the fourteen Eimeria species described as specific to sheep are indistinguishable from each other by eye and only two species - E. ovinoidalis and E. crandallis, are actually pathogenic.1 For this reason, diagnosing coccidiosis based on clinical signs of diarrhoea and oocysts in their faeces alone can generate false positives. This could lead to important differentials, such as Nematodirus battus infection (for lambs at pasture) being left untreated.
According to the company, false negatives are also a concern, particularly as prompt treatment of clinical cases with an anti-coccidial, such as diclazuril (Vexocan® 2.5mg/ml oral suspension) has been proven to reduce the convalescence period.2 Shedding of oocysts varies with disease progression and faecal counts can fluctuate significantly.3 For example, a delay between the development of clinical signs and oocysts appearing in faeces is common. Another possibility is sub-clinical disease, with affected lambs showing no typical outward signs. The gut damage caused by the parasite can be significant in these animals though, adversely affecting growth rates.
Elanco says that for reliable diagnosis of coccidiosis, faecal oocyst counts should be considered alongside disease and farm history, followed with Eimeria species identification if possible. The disease typically affects groups of lambs aged between 3-8 weeks old and is often triggered by a stressor such as castration, weaning, turnout and/or bad weather. If clinical signs appear around three weeks after such an event, the suspicion of coccidiosis can be heightened. For some farms, predictable stressors cause disease outbreaks year after year and in these cases, a metaphylactic dose of Vecoxan® can be administered to susceptible lambs 14 days after the trigger event.
Finally, the company says veterinary surgeons should also not forget the importance of good management when advising farmers about coccidiosis control. Lambing pen and high traffic area hygiene and age batching lambs are essential for long term control.
References
Life Technologies has announced the launch of a new ELISA test for bluetongue virus (BTV) antibodies.
According to the company, studies have confirmed that the LSI VET Ruminant Bluetongue II-serum ELISA can detect antibodies to BTV in experimentally infected sheep after 6 days, and in cattle after 7-8 days - several days sooner than some other commercially available test kits, including the company's previous ELISA test which the new product has replaced.
Life Technologies asked the UK's Pirbright Institute, the European Union Reference Laboratory for BTV, to conduct a preliminary assessment of the new test. The new test was able to detect antibodies in all 24 BTV reference sera and BTV 26 held by Pirbright, and showed high sensitivity in a longitudinal study of experimentally infected animals.
The Pirbright study also demonstrated that the LSI VET Ruminant Bluetongue II-serum ELISA could detect BTV antibodies in cattle and sheep that had been vaccinated with an inactivated Bluetongue vaccine.
The new test was developed by Life Technologies Animal Health in its research laboratory near Lyon in France and will be available in EU countries via Life Technologies Animal Health distributors according to local regulatory requirements (see www.lifetechnologies.com/lsi-animal-health) for details.
Norbrook Laboratories Ltd has launched the 2013 - 2014 edition of its UK Veterinary Surgeon's Product Compendium.
The compendium contains data sheets for the complete range of over 120 Norbrook products which are available in the UK and Northern Ireland, including 17 new products which have been launched since the last compendium was issued.
The compendium is available from your Norbrook representative or can be downloaded from www.norbrook.com. Norbrook also offers an iPhone App through which users can access essential product information including pharmaceutical presentation, uses, dosage and administration, withdrawal periods, contraindications & warnings and pharmaceutical precautions.
Ceva Animal Health has launched its 2013 ReprodAction desktop calendar, with a droll take on cycling cows.
The calendar is available free of charge to vet practices.
If you haven't received your calendar yet, contact Ceva Animal Health on 01494 781510 or email cevauk@ceva.com.
Ceva Animal Health has published Causes of scour in growing pigs: an overview, a technical review on pig scour.
The company says its aim is to provides vets with an easy-reference guide to the main causes and clinical signs of this common and potentially fatal condition.
At best, scour in growing pigs can cause significant weight loss and damage to the intestinal mucosa. At worst it will result in high mortality. Causes of scour in growing pigs: an overview summarises the causative agents of scour throughout the stages of growth, from sucking piglets through to finisher pigs.
Ceva adds that although it is difficult to be too prescriptive about assigning clinical signs to specific diseases because of variable immunity and the occurrence of mixed infections, the review provides useful guidelines to aid accurate diagnosis. Preventative management strategies are also discussed where applicable.
For further product information contact your local Ceva representative or Ceva Animal Health Ltd, Unit 3, Anglo Office Park, White Lion Road, Amersham, Bucks, HP7 9FB, Telephone +44 (0) 1494 781510.
Expert speakers at Advances in Diagnostics, a meeting held in Brussels last month, have said that molecular technology will play a vital role in safeguarding the health and productivity of food animals in the future.
Dr Willie Loeffen, President of the European Association of Veterinary Laboratory Diagnosticians (EAVLD) said: "Technology is taking over. Laboratory diagnosis used to be 99% labour and 1% technology, nowadays the emphasis is the other way around. Technology is now an integral and indispensable part of veterinary laboratories."
Dr Loeffen used the investigation of PRRSV infection in pigs and the more recent appearance of Schmallenberg virus in Europe to highlight how modern molecular techniques could help to characterise new disease threats rapidly.
"It took four years of laborious work for us to characterise the cause of PRRS, but thanks to sequencing technology Schmallenberg virus took just a few months.
"Technological developments mean that diagnosticians now do things that they could only dream about 10 or 20 years ago."
As well as providing a means of identifying new disease threats quickly, the meeting highlighted the increasing role of diagnostic tools as an integral part of maintaining animal health.
Dr Kirk Adams, Director of Product Management at Life Technologies, the meeting sponsor, said: "Diagnostics are no longer just a way of finding out what an animal died of - they have a multitude of uses on farm. They mean that we can take a more holistic and proactive approach to animal health; in contrast to the reactive, disease-driven approach of the past.
"As just one example, better diagnostics allow a more targeted approach to treatment, and the potential to reduce the use of broad-spectrum drugs - such as certain antibiotics - and thus comply with the wishes of consumers and legislators."
Dr Adams said that modern diagnostic tools also provided the means to improve vaccination programmes and biosecurity, and were essential for disease eradication schemes and for improving herd health status, for example by identifying persistently infected, asymptomatic animals.
They also enable veterinary surgeons to monitor herd health and build up an accurate and dynamic picture of health status and risk profile - and screen for emerging disease threats.
Dr Adams added: "Veterinarians now have access to a wider range of better diagnostics than ever before. Tests are now faster, more accurate and more precise than ever before.
"The next twenty years could see the biggest change in the way we manage production animals in over a hundred years."
The meeting was also addressed by Dr Kees van Maanen, from the Netherlands Animal health Service (GD), an expert in modern diagnostic technology and its application on both local and national levels. He called for greater international co-operation to protect European animals against threats from increasing global interaction. He said: "Pathogens and insects do not respect borders: trusting each other's results requires further harmonization and transparency for diagnostic procedures between laboratories and countries.
"Rapid and accurate diagnosis contributes to disease management, but does not stop epidemics. However, it has contributed significantly to gaining insight into the epidemiology of emerging diseases and formulating appropriate measures.
"The development of modern diagnostics has given us the potential to manage animal health and control infectious diseases in production animals far more effectively in the past - both on a local level and a national or regional level. Recent experience with unexpected disease outbreaks has shown that we can now characterise and track pathogens far more quickly and accurately than ever before.
"However, we need to make sure that we keep veterinarians and farmers informed about these developments, so they know how to apply them in practice in order to make the most of them.
"Diagnostics will continue to become a more integral part of animal health management in the next decade, we just need to make sure we can apply that knowledge in the best possible way."
Phil Kenward from Farm Vets South West in Bridgewater, Somerset has won a bottle of port from the Veterinary Benevolent Fund for submitting the best practical veterinary tip.
The tip was:
"Do not allow the owner's diagnosis of his problem to worry or influence you before you examine the animal yourself."
The competition was run to celebrate the launch of The Pocket Book of Tips For Practising Vets which can be ordered on-line from the Vetlife website to raise funds for the VBF charity.
Lydia Brown, President of the VBF, said: "This book has been a monumental effort by six mixed practice vets, to both share their experience with the profession and to provide very welcome funds for the veterinary profession's own charity, the VBF. We are currently raising money for the new Vet Helpline e-mail support service which will launch at the end of the year so we are extremely grateful to everybody concerned for all their efforts."
The Veterinary Marketing Association has announced a Practice Marketing Award, with a prize of £500 worth of CPD, for which entries are now being sought.
The award, which is sponsored by Merial, is open to companion and farm animal practices that can demonstrate effective marketing to their clients during the course of 2012.
For more information, visit: www.vma.org.uk/awards, or email: secretary@vma.org.uk for entry details.
Novartis Animal Health has been found in breach of the National Office of Animal Health Code on promotion.
The complaint related to a promotion at the National Sheep Association's 'Scotsheep 2012' on 6 June 2012, where Novartis had used the strapline 'Zolvix - the World's most effective wormer'.
The NOAH Committee unanimously took the view that the phrase constituted an all-embracing claim and a superlative which could not be substantiated.
Accordingly, the Committee found the promotion in breach of Clause 5.2.
The full details of the NOAH Committee's rulings is published on the NOAH website at www.noah.co.uk/code. The full report of this particular case will be available shortl.
Ceva Animal Health has launched ReprodAction, a new series of webinars to help address the problems commonly faced in bovine reproduction management.
James Husband, RCVS Specialist in Cattle Health and Reproduction, kicked off the series at the beginning of November with a live webinar for XLVet members: Assessing Fertility Records.
His presentation, which is now accessible to all large animal vets at http//onsync.digitalsamba.comn/go/ceva/ReprodAction, explores the common pitfalls and provides practical pointers for good fertility management. He discusses the limiting factors of oestrus detection, use of the calving interval as an assessor of individual fertility performance, implications of the varied definitions of conception rates, use of milk recording organisation data and the usefulness of the 21 day in calf rate.
Each webinar in the series is presented by a leading expert and has a facility for live chat and question and answer sessions.
For further information and details of when the next ReprodAction webinar will be taking place, contact Ceva Animal Health on 01494 781510 or email cevauk@ceva.com.
The badger culls planned to take place in West Somerset and West Gloucestershire this year have been postponed until 2013.
The postponement came at the request of The National Farmers Union (NFU), following new survey results which revealed higher than anticipated badger numbers in the two pilot areas (4,300 in West Somerset and 3,600 in West Gloucestershire ).
The NFU informed Defra that in light of these new figures they could not be confident of removing the required minimum 70% of the badgers in the two pilot areas this autumn.
Defra agreed to postpone the pilot culls until summer 2013 to allow farmers to continue their preparations and have the best possible chance of carrying out the cull effectively.
Environment Secretary Owen Paterson said: "Despite a greatly increased effort over the last few days and weeks, the farmers delivering this policy have concluded that they cannot be confident that it will be possible to remove enough badgers based on these higher numbers and considering the lateness of the season. It would be wrong to go ahead if those on the ground cannot be confident of removing at least 70% of the populations. Today I have received a letter from the President of the NFU, on behalf of the companies coordinating the culls, explaining why they do not feel they can go ahead this year and requesting that they be postponed until next summer. In these circumstances, it is the right thing to do and, as the people who have to deliver this policy on the ground and work within the science, I respect their decision.
"The Government is determined to tackle bovine TB by all the means available to us. Now, in the next few months, we will ensure that the pilot culls can be implemented effectively, in the best possible conditions, with the right resources. Having looked at all the evidence over many years, I am utterly convinced that badger control is the right thing to do, and indeed the higher than expected badger numbers only serve to underline the need for urgent action. I remain fully committed to working with the farming industry to ensure that the pilot culls can be delivered effectively, safely and humanely next summer."
The Government and NFU say they will now continue to plan so that the pilots can go ahead in Summer 2013.
Norbrook Laboratories has launched a ready-to-use suspension version of its Cefenil antibiotic.
Cefenil RTU (ceftiofur) is a 50mg/ml suspension for injection, indicated for cattle and swine.
Dr Barry McInerney, Norbrook's GB Veterinary Advisor said: "Cefenil RTU is a broad spectrum injectable antibiotic offering fast and effective treatment of bacterial respiratory disease, foot rot and acute post-partum metritis in cattle as well as bacterial respiratory disease in swine. It offers a zero milk withhold and a 5-day meat withhold which is the shortest on the market."
Norbrook's Cefenil Powder and Solution for Injection has been available for a number of years for the treatment of cattle and swine. It has recently been indicated for the treatment of BRD in horses in the UK. Cefenil RTU will offer vets an additional choice in the treatment of BRD.
Dr McInerney added: "Cefenil is a tried and tested antibiotic which vets have been using for a number of years. We are delighted to extend the Cefenil range with a RTU suspension for cattle and pigs and adding an indication for horses to our Cefenil Powder and Solution for Injection. It gives vets a wider choice for the treatment of BRD with a product with which they are already familiar."
For further product information, visit www.norbrook.com.
The BVA has welcomed the decision to prohibit the advertising of antimicrobials directly to animal keepers from 2013 in a bid to reduce antimicrobial resistance.
The Veterinary Medicines Directorate (VMD) announced that the Veterinary Medicines Regulations will be revised next year. The change has come as a result of the European Commission's view that the UK did not correctly transpose the European Directive 2001/82/EC which prohibits the advertising of certain veterinary medicinal products to the 'general public'.
When the VMD consulted on proposals to restrict the advertising of antimicrobials to farmers in 2010 the BVA supported the measure as a sensible approach to the responsible use of antimicrobials.
In a letter to stakeholders the VMD explained that: "A number of interested parties from veterinary medicine hold the view that the advertising of antibiotics to keepers of animals leads to undue pressure to prescribe newer antibiotics, which can often be important in human medicine and are associated with the development of multiple resistances."
Peter Jones, President of the BVA, said: "The BVA has consistently argued for the restriction of advertising of antimicrobials to animal keepers and we believe this is the right decision.
"New antimicrobials are heavily advertised by pharmaceutical companies and there can be undue pressure put on veterinary surgeons by clients who want to try new products that promise good results, but which may not be appropriate from the point of view of responsible use.
"Antimicrobial resistance is a very serious issue for both animal and human health and we are pleased that the European Commission and the VMD have taken the view that the Regulations need to be revised.
"Ultimately, it is the veterinary surgeon who will make the decision on which veterinary products to use and vets will continue to work with their farm clients to ensure antimicrobials are used prudently and responsibly."
Pfizer Animal Health has launched Poulvac, the first modified live vaccine against E.coli in chickens.
The company claims that the vaccine, which can be used from one day of age, is set to bring major benefits in safeguarding the health of broilers, pullets for egg laying and breeding stock.
According to Pfizer, E.coli is one of the most significant bacterial pathogens found in chicks during the first week, leading to problems throughout the life of a flock including inferior performance, lack of uniformity and increased mortality. It is a costly, widespread problem for the UK poultry industry.
The vaccine was developed from research beginning in the 1990s at the Government's veterinary laboratories at Weybridge (now AHVLA) in the UK, employing genome technology to produce an avirulent strain of E.coli that induces protective immunity to the pathogenic strains of the bacteria.
The vaccine is completely non-pathogenic, and does not persist in the bird or the environment for any significant period of time. A gene deletion in its development restricts in vivo replication and leaves behind activated macrophages ready to respond to pathogenic E.coli strains.
Dr Stuart Andrews, poultry technical manager of Pfizer in the UK and Ireland said: "Poulvac E. coli provides broad cross protection against the key serotypes of E. coli infecting chickens. It is the only modified live, nonreactive vaccine proven to meet the European regulatory requirements for efficacy and safety.
"Trials have confirmed that Poulvac E.coli does not persist in the bird and proves to be self-limiting. The vaccine can survive in the environment for only a short time, and spread to in-contact birds is also limited."
The vaccine is administered as a coarse spray with onset of immunity 14 days afterwards and duration of immunity for up to 12 weeks. It can be used from day-old up to six weeks before the onset of lay, and has a nil day withdrawal period.
In the USA where Poulvac E coli has been available for six years field experience has shown the considerable benefits. In the Midwest where average layer mortality at 50 weeks of age was 2.31 per cent, this was reduced to 1.51 per cent with three doses of the vaccine*. In Eastern USA flock mortality compared with five previous flocks was reduced from over three per cent to one per cent.
A field trial in the USA with more than 300,000 broiler breeders vaccination before lay reduced mortality from 2.8 to 1.9 per cent - with only two out of 28 flocks needing antibiotic treatment compared with 13 of the 28 unvaccinated flocks.
On a broiler field trial in Georgia over four million birds were vaccinated with Poulvac E. coli at hatch. The vaccinated birds had a better feed conversion (1.79 against 1.84 for the controls) and with condemnations at the processing plant down from 1.22 to 0.73 per cent the result was a lower production cost of 0.51¢ per lb.
In another broiler trial covering more than two million birds in Arkansas livability was improved from 95.20 to 95.77 per cent and feed conversion improved from 1.95 to 1.90, gaining 0.45¢ per lb.
* Pfizer says it is important to note that in these studies carried out in the USA more than one dose of the vaccine was often administered. A single vaccination is licensed in the Summary of Product Characteristics however, where clinical disease requires and at the discretion of a veterinary surgeon, the vaccination schedule may be re-started as there is no contra-indication on the SPC.
Norbrook Laboratories has launched Norfenicol Solution for Injection (florfenicol), a broad spectrum antibiotic licensed for the treatment of pneumonia in cattle and pigs.
Dr Barry McInerney, Norbrook's GB Veterinary Advisor said: "With many farmers preparing for winter housing, the launch of Norfenicol is timely as pneumonia represents the most common disease of housed cattle in the UK costing the agricultural industry an estimated £80m per year. Norfenicol is an easy to inject, cost effective treatment of pneumonia which kills bacteria quickly, and is available in a durable plastic bottle. Studies have shown florfenicol, the active ingredient in Norfenicol, to have a high bacteriological and clinical efficacy (100% and 96% respectively) against susceptible bacteria in the treatment of calf respiratory tract diseases."
Norfenicol is indicated for the treatment of bacterial respiratory disease in cattle associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somniand for the treatment of acute outbreaks of respiratory disease caused by strains of Actinobacillus pleuropneumoniae, and Pasteurella multocida in swine.
Dr McInerney added: "NSAIDs have also been shown to be a beneficial ancillary therapy in treating bacterial pneumonia, to alleviate pain as well as to reduce inflammation and pyrexia. Norbrook has a range of NSAID products which are available as an adjunctive treatment for pneumonia in cattle, including Loxicom 20 mg/ml solution for injection for cattle, pigs and horses."
For further product information, visit www.norbrook.com
The Royal College of Veterinary Surgeons (RCVS) has clarified the legal position regarding the disbudding of goats, following recent media reports concerning undercover filming on UK goat farms.
The carrying out of any activity which amounts to veterinary surgery is restricted to veterinary surgeons unless there is a suitable exemption that allows other people to do it. The removal of the horn-bud of goats (disbudding) is considered veterinary surgery under the provisions of the Veterinary Surgeons Act 1966 (the Act).
Schedule 3 of the Act provides certain exemptions to the restriction on carrying out veterinary surgery, such as those allowing veterinary nurses and student veterinary nurses to undertake any medical treatment or any minor surgery (not involving entry into a body cavity) in certain circumstances. However, Schedule 3 specifically provides that these exemptions do not allow non-veterinary surgeons to undertake the disbudding of goats, except the trimming of the insensitive tip of an in-growing horn which, if left untreated, could cause pain or distress.
There are no other Exemption Orders covering the disbudding of goats and therefore this procedure may only be undertaken by veterinary surgeons.
The Mutilations (Permitted Procedures) (England) Regulations 2007, the Mutilations (Permitted Procedures) (Wales) Regulations 2007 and the Prohibited Procedures on Protected Animals (Exemptions) (Scotland) Regulations 2007 all include disbudding of goats as a procedure which can be carried out for non-therapeutic reasons. However, this secondary legislation is subject to the restrictions in the Veterinary Surgeons Act 1966 and therefore disbudding of goats is restricted to veterinary surgeons.The Welfare of Animals (Permitted Procedures By Lay Persons) Regulations (Northern Ireland) 2012 currently include disbudding of goats as a procedure which may be carried out by non-veterinary surgeons. However, the Veterinary Surgeons Act 1966 applies to Northern Ireland and the Regulations are scheduled to be amended later in 2012. This will make it clear that only veterinary surgeons may disbud goats in the UK.
The secondary legislation in the UK does not explicitly require anaesthetic to be administered when disbudding goats. However, disbudding should be carried out by veterinary surgeons in accordance with good practice and in such a way as to minimise pain and suffering caused to the animal, which should include use of an anaesthetic.
In summary, only a veterinary surgeon may undertake the disbudding of goats and due to the nature of the procedure, veterinary surgeons disbudding goats should administer anaesthetic.
Bulk milk surveillance for stomach worm exposure in dairy cows has found high levels in 68% of herds, with "probable sub-clinical effects on health and production", according to Pfizer Animal Health.
Between September 2011 and March this year, 449 milk samples submitted by dairy vets and SQP animal health advisers were analysed independently for Pfizer VPS.
Pfizer VPS vet Andrew Montgomery says that stomach worm (Ostertagia ostertagi) is the species identified most often in dairy cows1,2. and known to suppress appetite3: "Numerous trials have found a yield response to worming treatment, typically in the region of 1kg/cow/day."4
"At 25p/litre, this would be worth £76/cow over a 305-day lactation, or about £16,500/year in a typical 200-cow herd. Some trials have also identified improvements in reproductive performance although this remains to be proven absolutely."4
When test results indicate that worming is justified, Andrew recommends a moxidectin pour on treatment in the late dry period to maximise the gain over the highest yielding, early part of lactation.
The bulk milk surveillance programme is ongoing, and free Pfizer test kits are available from participating VPS animal medicine suppliers and veterinary practices.
The Badger Trust's legal challenge to Defra's plans for targeted badger cull pilots has failed in the High Court on all three grounds.
Whilst the RSPCA has expressed its disappointment, the British Veterinary Association and British Cattle Veterinary Association have welcomed the judgement.
BVA President Carl Padgett said: "We are pleased that the High Court has ruled Defra's policy lawful and that the pilot badger culls can now go ahead.
"The BVA and BCVA believe that the government's approach has been robust and justifiable as it is based on our current scientific knowledge.
"Bovine TB is a devastating disease and we must tackle the disease in wildlife alongside cattle controls if we are to get on top of it."
David Bowles, the RSPCA's Director of Communications, said: "We are bitterly disappointed that the UK Government in England is ploughing on with plans to kill badgers but the fight is not over yet.
"We believe culling is not a long-term, sustainable solution and will be of little help in reducing the disease - perhaps even making things worse in some areas. It will wipe out huge numbers of this much-loved species, virtually eliminating badgers from these areas, including many animals which are healthy.
"It is not as if there aren't alternatives to a cull. Vaccination could be a more effective and sustainable way of dealing with the disease, and one which does not involve killing most of the badger population in very large areas of the countryside."
MSD Animal Health has launched a new Chronogest CR pack for practices starting a dialogue with sheep producer clients about planned breeding for 2013 lamb sales, and is offering a free applicator with every four packs purchased.
The Chronogest CR intra-vaginal sponges, impregnated with 20mg of cronolone (flugestone acetate) synthetic hormone, are now available in foil wrapped packs of 25. The packs protect the sponges from light and moisture.
MSD is reminding practitioners that sponging programmes must be planned at least six weeks in advance of mating, with PMSG-Intervet injections essential at sponge removal.
The new packs of 25 will be available when existing 25, 50 and 100 pack sizes sell out.
Further information on planned breeding - including newsletter copy and sheep producer advisory materials - is available from the MSD Animal Health veterinary support group (VSG) on 01908 685685 or via emailing vet-support.uk@merck.com
Norbrook Laboratories has launched a long-acting cattle bolus which it says will reduce the risk of Milk Fever.
According to the company, Calcitrace D3 is the first and only long-acting bolus to offer slow and fast releasing calcium to provide sustained calcium levels for 48 to 72 hours. In addition, Calcitrace D3 provides Magnesium, Phosphate and Vitamin D3 making it the most comprehensive bolus available.
Calcitrace D3 is smooth gelatin coated bolus with a rounded tip designed for easier administration. Norbrook says it is smaller than other boluses making it less likely to cause trauma on the orpharynx during administration.
Dr Barry McInerney, Norbrook's GB Veterinary Advisor said: "Milk Fever is a common metabolic disorder in dairy cattle which generally affects older, high producing cows and is caused by a rapid decrease in calcium concentrations in the blood just before calving. It is estimated that 3-10% of cows are affected by Milk Fever with a cost of more than £200 per incident so it is crucial that farmers and vets reduce the risk as effectively as possible.
"Norbrook's new Calcitrace D3 bolus which should be administered just before calving, provides higher calcium blood levels during the critical 12 - 48 hour post calving period and provides sustained increased levels for well beyond 48 hours. With the addition of Magnesium, Phosphate and Vitamin D3, Calcitrace D3 provides additional protection against Milk Fever."
Andrew Hillan MVB MRCVS, Director of Veterinary Sciences at Norbrook, led the development of Calcitrace D3. He said: "The launch of Calcitrace D3 is another illustration of the very high quality of technical expertise that exists within our research and development department and underlines Norbrook's commitment to developing high quality and innovative products. It comes from a strong and exciting pipeline of new products which we will bring to the market over the next couple of years."
MSD Animal Health has obtained regulatory approval in 21 European countries, including the UK, for Cobactan LA 7.5% (cefquinome) - a new-generation, injectable antimicrobial for the treatment of swine respiratory disease (SRD).
Raul Berro DVM, global marketing director swine at MSD Animal Health said: "Cobactan LA 7.5% is a long-acting version of our highly effective Cobactan 2.5%. Its longer duration of action means greater compliance for swine producers with fewer injections and less stress to the animals, without sacrificing performance."
According to the company, the long-acting antibiotic formulation is effective against three major SRD pathogens in growing and finishing pigs - Actinobacillus pleuropneumoniae, Haemophilus parasuis and Pasteurella multocida. Considered the most important threat to the swine industry worldwide, SRD causes increased mortality, decreased weight gain and increased feed consumption.
Cobactan LA 7.5% requires two intramuscular injections 48 hours apart, compared to Cobactan 2.5%, which requires three daily injections. The recommended dose rate is 1 mL (3 mg cefquinome) per 25 kg bodyweight. The product isavailable in 50-ml, 100-ml and 250-ml glass vials.
Raul aded: "COBACTAN LA 7.5% also has a short withdrawal period of seven days. This makes the injectable product also safe to use throughout the finishing period for the treatment of SRD."
MSD adds that the use of COBACTAN LA 7.5% should be according to established responsible use guidelines and strictly according to the label instructions where specific restrictions apply to this class of antibiotics.
For more information, contact your local MSD Animal Health representative or go to www.msd-animal-health.com.
Edinburgh-based charity the Global Alliance for Livestock Veterinary Medicines (GALVmed) has announced three drug discovery contracts in an effort to combat animal African Trypanosomosis (AAT), a disease which is estimated to cost Africa US$5billion a year.
Animal African trypanosomosis, transmitted by the tsetse fly, is a parasitic disease which affects livestock, resulting in a chronic illness which often ends in death. An estimated 50 million cattle and 70 million sheep and goats are at risk, with around 3 million cattle dying annually from the disease.
AAT causes economic losses in livestock, reducing meat and milk production and leaving animals so weak they are unable to help cultivate land. It affects over 10 million square kilometres of fertile land spread across nearly 40 countries in Africa and therefore has a huge impact on food and nutritional security and livelihoods across the continent.
The drugs that are currently used were developed in the 1950s and 60s and drug resistance is now a commonly reported problem. With few other options available, these drugs are the most important method of controlling the disease.
In May 2011 the Department for International Development (DfID) awarded GALVmed 30 month grant for £8million to facilitate the development of drugs, diagnostics and potential vaccines for the control of AAT.
The first contract was awarded to Anacor Pharmaceuticals Inc., a California based biopharmaceutical company established in 2002.
As part of a Drugs for Neglected Diseases Initiative (DNDi) supported project, Anacor and their partners discovered a series of compounds to combat the human form of AAT, Human African Trysanosomsis (HAT). A number of compounds produced under this programme have properties which could make them suitable for the treatment and prevention of animal AAT. These relevant compounds will now be screened for efficacy and safety under the GALVmed contract.
The second and third contracts have both been awarded to the College of Life Sciences at the University of Dundee, one of Europe's top-ranked universities for life science research.
Dr Kevin Read, who is Head of Drug Metabolism and Pharmokinectics at the drug Discovery Unit is leading a piece of drug discovery and development research, which aims to develop new drugs for the treatment and possible prevention of AAT in cattle, and also a diagnostic test for use in the field. This builds on the university's work on HAT and drugs that were unsuitable for human treatment are now being re-evaluated as potential drugs for cattle.
Dr Read said: "I am very excited to be working in partnership with GALVmed to apply our extensive drug discovery expertise in HAT to identify and bring forward new potential drugs for the treatment and prevention of AAT. The new project offers an exciting opportunity to reposition compounds showing great promise for the treatment of first stage HAT into AAT, thus improving food security in some of the poorest countries in sub-Saharan Africa."